Market Overview:
The global arginase deficiency treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of arginase deficiency, rising awareness about the disease, and growing demand for effective treatments. The global arginase deficiency treatment market is segmented on the basis of type into oral and injection therapies. The oral therapy segment is expected to dominate the global arginase deficiency treatment market during the forecast period owing to its ease of use and lower cost as compared to other therapies. However, the injection therapy segment is projected to grow at a higher CAGR due its superior efficacy over other therapies. On the basis of application, hospitals are expected to account for majority share in terms revenue in 2018 followed by drugs stores and other applications segments respectively.
Product Definition:
Arginase deficiency is a rare inherited disorder that affects the body's ability to break down protein. Treatment for arginase deficiency usually includes a special diet and supplements.
Oral:
Oral is a form of medication which is taken into the body by mouth. It may be administered in various ways such as tablets, capsules, syrups or injections. The drug substance (active pharmaceutical ingredient) can be sourced from natural sources or synthetic sources. Oral drugs are usually easy to manufacture and require less time for approval by the Food and Drug Administration (FDA) compared to other forms of medication such as injectable and intravenous among others.
Injection:
Injection is a medical procedure used to deliver a specific amount of argon gas to the blood vessels supplying the tissue or organ. It is also used in cases where there are no blood vessels present. The treatment for argon deficiency consists of injections every two to three days until clinical improvement occurs.
Application Insights:
The other application segment accounted for the largest share of the global arginase deficiency treatment market in 2017. This can be attributed to growing awareness about oral medication and increasing healthcare spending in emerging economies, such as India and China. As per a study published by World Health Organization (WHO) in 2016, out of 1 USD spent on healthcare, around 70 cents goes towards medical care while 29 cents is spent on pharmaceuticals and related products. Increasing government initiatives to control expenditure is expected to further drive demand over the forecast period.
Drug stores are anticipated to be one of the fastest-growing segments owing to high product demand from countries such as Brazil, Argentina, Chile and Mexico where it is used for treating diseases relatedto blood vessels & heart valves among others including kidney disease caused by diabetes mellitus type 2 or chronic renal failure (CRF).
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in prevalence of lifestyle-associated diseases, such as diabetes and obesity. According to the CDC, around 29.6 million people were diagnosed with diabetes in 2015 and it is estimated that around 7.5 million people have been newly diagnosed with diabetes since 2011.
The key players operating within this region are Argiways (India) Pvt Ltd.
Growth Factors:
- Increasing prevalence of arginase deficiency
- Growing demand for effective and affordable treatment options for arginase deficiency
- Rising awareness about the availability of treatments for arginase deficiency
- Technological advancements in the field of arginase deficiency treatment
- increasing investment in research and development activities to develop new and better treatment options for arginase deficiency
Scope Of The Report
Report Attributes
Report Details
Report Title
Arginase Deficiency Treatment Market Research Report
By Type
Oral, Injection
By Application
Hospital, Drugs Stores, Other
By Companies
Helsinn Healthcare, Novartis Pharmaceuticals, Horizon Pharma, Medicis Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Arginase Deficiency Treatment Market Report Segments:
The global Arginase Deficiency Treatment market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Helsinn Healthcare
- Novartis Pharmaceuticals
- Horizon Pharma
- Medicis Pharmaceutical
Highlights of The Arginase Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Drugs Stores
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Arginase Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Arginase deficiency is a rare genetic disorder that results in the inability to break down arginine, an amino acid. This can lead to high levels of arginine in the blood and tissues, which can cause serious health problems. Treatment for arginase deficiency typically involves taking supplements or medications to help increase the body's ability to break down arginine.
Some of the key players operating in the arginase deficiency treatment market are Helsinn Healthcare, Novartis Pharmaceuticals, Horizo​​n Pharma, Medicis Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Arginase Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Arginase Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Arginase Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Arginase Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Arginase Deficiency Treatment Market Size & Forecast, 2018-2028
4.5.1 Arginase Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Arginase Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Arginase Deficiency Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Arginase Deficiency Treatment Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Arginase Deficiency Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Arginase Deficiency Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Arginase Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Arginase Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Arginase Deficiency Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Arginase Deficiency Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Arginase Deficiency Treatment Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Arginase Deficiency Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Arginase Deficiency Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Arginase Deficiency Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Arginase Deficiency Treatment Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Arginase Deficiency Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Arginase Deficiency Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Arginase Deficiency Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Arginase Deficiency Treatment Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Arginase Deficiency Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Arginase Deficiency Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Arginase Deficiency Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Arginase Deficiency Treatment Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Arginase Deficiency Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Arginase Deficiency Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Arginase Deficiency Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Arginase Deficiency Treatment Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Arginase Deficiency Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Arginase Deficiency Treatment Market: Competitive Dashboard
14.2 Global Arginase Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Helsinn Healthcare
14.3.2 Novartis Pharmaceuticals
14.3.3 Horizon Pharma
14.3.4 Medicis Pharmaceutical
